絞り込み

16555

広告

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study.

著者 Guillot A , Joly C , Barthélémy P , Meriaux E , Negrier S , Pouessel D , Chevreau C , Mahammedi H , Houede N , Roubaud G , Gravis G , Tartas S , Albiges L , Vassal C , Oriol M , Tinquaut F , Espenel S , Bouleftour W , Culine S , Fizazi K
Clin Genitourin Cancer.2018 Sep 06 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

About one-third of patients with renal cell carcinoma (RCC) have detectable metastases at diagnosis. Among them, bone is the second most frequent metastatic site. Treatment of metastatic RCC mostly relies on anti-angiogenic (AA) therapies and, more recently, immunotherapy. Skeletal-related events (SREs) can be prevented with bone-targeted therapies such as denosumab (Dmab), which has demonstrated superiority when compared with zoledronic acid in solid tumors. However, there is limited available data on Dmab toxicity in combination with AA therapies in patients with kidney cancer. The objective of this study was to retrospectively analyze the toxicity profile (mainly osteonecrosis of the jaw [ONJ] and hypocalcemia) in patients with metastatic renal cell carcinoma (mRCC) treated with Dmab and AA therapy combination.
PMID: 30279115 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード